Ganetespib Window of Opportunity Study in Head and Neck Cancers
Public ClinicalTrials.gov record NCT02334319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study identification
- NCT ID
- NCT02334319
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Emory University
- Other
- Enrollment
- 3 participants
Conditions and interventions
Conditions
- Stage I Hypopharyngeal Squamous Cell Carcinoma
- Stage I Laryngeal Squamous Cell Carcinoma
- Stage I Oral Cavity Squamous Cell Carcinoma
- Stage I Oropharyngeal Squamous Cell Carcinoma
- Stage II Hypopharyngeal Squamous Cell Carcinoma
- Stage II Laryngeal Squamous Cell Carcinoma
- Stage II Oral Cavity Squamous Cell Carcinoma
- Stage II Oropharyngeal Squamous Cell Carcinoma
- Stage III Hypopharyngeal Squamous Cell Carcinoma
- Stage III Laryngeal Squamous Cell Carcinoma
- Stage III Oral Cavity Squamous Cell Carcinoma
- Stage III Oropharyngeal Squamous Cell Carcinoma
- Stage IVA Hypopharyngeal Squamous Cell Carcinoma
- Stage IVA Laryngeal Squamous Cell Carcinoma
- Stage IVA Oral Cavity Squamous Cell Carcinoma
- Stage IVA Oropharyngeal Squamous Cell Carcinoma
Interventions
- Ganetespib Drug
- Therapeutic Conventional Surgery Procedure
- Laboratory Biomarker Analysis Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 19 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Jan 31, 2016
- Completion
- Jan 31, 2016
- Last update posted
- Jul 25, 2016
2014 – 2016
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02334319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02334319 live on ClinicalTrials.gov.